TD Asset Management
EWTX icon

TD Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

TD Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,200
Closed -$730K – 1215
2025
Q1 		$730K Buy
+33,200
New +$871K ﹤0.01% 1107

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TD Asset Management's EWTX Position: Q2 2025 in Review

TD Asset Management sold out of Edgewise Therapeutics (EWTX) in Q2 2025, closing a stake of 33,200 shares — an estimated $730K sold.

TD Asset Management first reported a position in EWTX in Q1 2025 and held it in 1 quarter. The position peaked at $730K in Q1 2025. 178 funds tracked by Wall St. Rank hold EWTX as of Q2 2025.

  • TD Asset Management reported no remaining Edgewise Therapeutics position as of Q2 2025 after selling out during the quarter.
  • TD Asset Management sold 33,200 Edgewise Therapeutics shares in Q2 2025, an estimated $730K.
  • TD Asset Management first reported a position in Edgewise Therapeutics in Q1 2025 and held it in 1 quarter.
  • TD Asset Management's Edgewise Therapeutics position peaked at $730K in Q1 2025.
  • 178 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2025.

Based on TD Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.